Dainippon Sumitomo Pharma
11
51M
9
0.46
2
0.18
2
- Areas of investment
Summary
Dainippon Sumitomo Pharma is the famous Corporate Investor, which was founded in 1997. The fund was located in Asia if to be more exact in Japan. The leading representative office of defined Corporate Investor is situated in the Osaka.
The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Dainippon Sumitomo Pharma, startups are often financed by WERU Investment, SMBC Venture Capital, Real Tech Fund. The meaningful sponsors for the fund in investment in the same round are tella, Shin Nippon Biomedical Laboratories (SNBL), Nikon.
Among the most successful fund investment fields, there are Health Care, Biotechnology. The fund has exact preference in some founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight Edison Pharmaceuticals, Meltin MMI, Healios K.K. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Japan.
The real fund results show that this Corporate Investor is 47 percentage points more often commits exit comparing to other companies. The fund is constantly included in less than 2 investment rounds annually. The top activity for fund was in 2013. Despite it in 2019 the fund had an activity. The increased amount of exits for fund were in 2015. The usual things for fund are deals in the range of 10 - 50 millions dollars. Comparing to the other companies, this Dainippon Sumitomo Pharma performs on 4 percentage points more the average number of lead investments.
Investments analytics
Analytics
- Total investments
- 11
- Lead investments
- 2
- Exits
- 2
- Rounds per year
- 0.46
- Follow on index
- 0.18
- Investments by industry
- Health Care (10)
- Biotechnology (8)
- Medical (6)
- Medical Device (2)
- Product Research (2) Show 7 more
- Investments by region
-
- United States (4)
- United Kingdom (1)
- Japan (6)
- Peak activity year
- 2014
- Number of Unicorns
- 1
- Number of Decacorns
- 1
- Number of Minotaurs
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Avg. valuation at time of investment
- 755M
- Group Appearance index
- 0.73
- Strategy success index
- 0.40
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| AlphaNavi Pharma | 05 Apr 2019 | Health Care, Pharmaceutical, Product Research | Early Stage Venture | 8M | Japan, Kyoto, Kyoto Prefecture |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.